Association of Contraception with Medical Conditions
FSRH CEU Response to published study: Maternal use of hormonal contraception and risk of childhood leukemia: a nationwide, populate-based cohort study - September 2018
A Danish database study suggests that children born to women who have used hormonal contraception (HC) in the three months prior to conception or in early pregnancy are at increased risk of developing childhood non-lymphoid leukaemia compared with children whose mothers have never used HC. The FSRH CEU provides a critical appraisal of the study in this statement.
This document is up-to-date
FSRH CEU Statement to published systematic review: The relationship between progestin hormonal contraception and depression: a systematic review - March 2018
Much recent media attention has been given to the subject of a potential association between hormonal contraception and depression. The FSRH CEU monitors and reports relevant emerging evidence. A new systematic review published in Contraception examines the existing evidence relating to risk of depression associated with use of progestogen-only contraception (POC).1 The authors of the review conclude that the bulk of the evidence does not support an association between use of POC and depression based on validated measures. Meta-analysis was not possible due to the heterogeneity of studies.
CEU Statement: Glioma and Hormonal Contraception (February 2015)
Gliomas are glial cell tumours which can occur in the spinal cord or the brain and are the most common type of brain tumour. They vary greatly in their likely rate of growth, differentiation and prognosis. Glioblastoma multiforme is the most common and most aggressive primary brain tumour.
CEU Statement: Depot Medroxyprogesterone Acetate (DMPA, Depo- Provera) and Risk of HIV Acquisition (January 2015)
Progestogen-only injectable contraception is widely used across the world and is particularly popular in resource poor countries with a high incidence of HIV infection e.g. in sub-Saharan Africa. It is clearly important therefore to establish whether there is any relationship between the use of injectable contraception and increased risk of HIV acquisition.
CEU Statement: HIV and Progestogen-only Contraceptives (March 2014)
An article published in the British Medical Journal (BMJ) in November 2013, questioned whether women with HIV, or at high risk of contracting HIV, should use progestogen-containing contraceptives.
CEU Statement: Oral Contraceptives and Multiple Sclerosis (March 2014)
Various news stories have reported the findings detailed in the AAN press release which stated that compared to women who did not use hormonal contraceptives, women who did, were 35 percent more likely to develop Multiple Sclerosis and that the findings suggested that hormonal contraception may be contributing to the rise in the rate of MS among women.
CEU response to published study: Association of Hormonal Contraception with Depression
This statement is a CEU response to a study published in JAMA Psychiatry titled Association of Hormonal Contraception with Depression.
FSRH CEU Statement: Response to Study Contemporary Hormonal Contraception and the Risk of Breast Cancer (December 2017)
FSRH's Clinical Effectiveness Unit (CEU) reviews an observational study published in the New England Journal of Medicine. The study reports that, in the Danish study population, women who were currently using any method of hormonal contraception* (HC) or had done so within the last 6 months were 20% more likely to be diagnosed with breast cancer than those who had never used HC.
FSRH CEU Statement: Response to Study Intrauterine Contraception Use and Cervical Cancer Risk - January 2018
This statement responds to a recent study that reported that women who had used intrauterine contraception (IUC) were over one third less likely to experience invasive cervical cancer than women who had not used IUC. The study has received media attention and the FSRH CEU considered it important to put the findings into perspective. January 2018